Streamlining Your Process Development Journey to GMP Manufacturing
Moving a biopharmaceutical product from molecule-to-market is demanding in terms of expertise and capabilities needed throughout the development and manufacturing process. In this white paper, we explore the processes, operations, and customer-focused approach of Emergent CDMO's integrated internal teams, providing efficient organization alongside smooth and timely technology transfer and scale-up, from R&D to GMP manufacturing. Download our latest white paper to learn how partnering with an integrated CDMO can help create an efficient development services framework to achieve your drug substance and drug product manufacturing goals.
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERY
February 14th 2025Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering greater patient comfort and adherence to expand the therapeutic market.
Flexible-Dose Development Strategies for Today's Clinical Landscape - Executive Summary
January 8th 2025This executive summary focuses on dose-flexible manufacturing strategies and their role in drug development. Dose flexibility is increasingly important for early clinical studies, particularly in areas such as pediatric medicines and oncology. However, flexible dosing strategies are often neglected or not prioritized early in development. This presentation will focus on technical strategies that can help anticipate appropriate timing for implementation and how to do so cost effectively while adhering to required timelines.
